Project
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Ongoing - recruitment active · 2024 until 2028
Schittenhelm Marcus, Dei Cas Alissa
Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2028
Financing
Industry
Labels
leukemia